



Supplementary Fig. S2. DGKA knockdown sensitizes ovarian cancer cells to chemotherapy agents but not proteasome inhibitor or mTOR inhibitor. Effect of DGKA knockdown on response to anticancer agents including gemcitabine (A), paclitaxel (B), bortezomib (C), and rapamycin (D). Drug sensitivity was assessed by IC_{50} of each drug (*left panels*). Cell viability (*middle panels*) and levels of DGKA downstream effectors (*right panels*) including c-JUN phosphorylation and WEE1 expression were determined in cells with DGKA knockdown and sublethal doses of gemcitabine (1 μ M), paclitaxel (5 nM), bortezomib (25 nM), and rapamycin (30 nM) treatment. $n=3$ technical replicates. Results of one representative experiment from two independent experiments are shown. Error bars represent SD. P values were determined by one-way ANOVA (ns: not significant; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$).